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INTRODUCTION
Vigabatrin (VGB) is an antiepileptic drug that irreversibly
inhibits brain  -aminobutyric acid (GABA) transaminase (1).
VGB is used as first-line treatment for infantile spasms, espe-
cially those secondary to tuberous sclerosis, and as an adjunct
therapy for medically resistant localization-related childhood
epilepsies (2). 
Following an initial report of 3 patients who experienced
concentric visual field losses following VGB treatment (3),
several additional studies showed visual field constriction
during VGB therapy. Cross-sectional studies have estimated
the prevalence of VGB-associated visual field defects (VFDs)
as 20-50% in patients receiving VGB mono- or adjunct ther-
apies. Various groups have found that longer treatment (4, 5)
and higher total doses (6-8) are associated with greater visual
field losses in adults, while other studies dispute these cor-
relations (9, 10). A characteristic pattern of ocular dysfunc-
tion has been observed in VGB-treated patients, including
peripheral visual field constriction primarily in the nasal area,
which is rarely seen in other conditions (11-13).
Although these studies have shown evidence of VGB-asso-
ciated VFD, VGB is highly effective and has a low occurrence
of side effects or metabolic interactions. Thus, it is still com-
monly used in the clinic, especially for treatment of infan-
tile spasms and tuberous sclerosis with intractable epilepsy.
Most studies on VGB-associated VFD to date have been per-
formed in adult patients, in part because it is difficult to esti-
mate the frequency of this condition in pediatric patients,
who are generally unable to cooperate in visual field testing.
Only a few studies have been attempted in pediatric patients.
We therefore sought to estimate the prevalence, type, sever-
ity, and risk factors of VGB-attributed VFDs in pediatric
patients.
MATERIALS AND METHODS
We retrospectively investigated the medical records of 67
pediatric epileptic patients who were treated with VGB at
the Department of Pediatrics of the Asan Medical Center and
had undergone ophthalmological examinations. For inclusion,
each patient was required to have a diagnosis of epilepsy, no
evidence of ophthalmologic disease upon initial examination,
and a history of treatment with antiepileptic drugs, including
VGB, during the observation period. Patients were excluded
if they had poor compliance or non-concentric VFDs, which
corresponded to brain organic lesions (e.g. intracranial hem-
orrhage). 
The enrolled patients had been given full ophthalmologic
examinations, including visual acuity, ophthalmoscopy, mea-
surement of intraocular pressure, and visual field examination
using program 30-2 of the Humphrey Field Analyzer. The
severities of the VGB-attributed VFDs were scored as Grade
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Vigabatrin and Visual Field Defects in Pediatric Epilepsy Patients 
We studied the prevalence, type and severity of vigabatrin (VGB)-attributed visual
field defects (VFDs), and used these data to assess the associated risk factors in
pediatric patients. Medical records were retrospectively reviewed for 67 pediatric
patients who received VGB alone or in combination with other antiepileptic drugs,
and who had undergone visual field examinations using a Humphrey visual field
analyzer. Of the 67 patients, 15 had VGB-attributed VFDs: 13 had nasal arcuate
type, 1 had nasal and temporal constricted type and 1 had nasal constricted type.
In terms of severity, 7 patients had Grade I VGB-attributed VFDs, 5 had Grade II,
2 had Grade III, and 1 had Grade IV. Although there were no significant differences
between the VFD and non-VFD groups with regards to all tested parameters, there
were no cases of VGB-attributed VFDs in patients with total treatment durations
<2 yr and cumulative doses <10 g/kg. In conclusion, the prevalence of VGB-attribut-
ed VFDs in VGB-treated pediatric epilepsy patients was 22%. The high frequency
of VGB-attributed VFDs indicates that physicians should inform all patients of this
risk prior to VGB treatment and perform periodic visual field examinations. 
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I (minimal, 25-30°), Grade II (moderate, 20-30°), Grade III
(moderate to severe, <20°), or Grade IV (severe, ring scotoma)
(Fig. 1). Data were analyzed by Fisher’s exact test and Student’s
t-test using SPSS, version 10.01.
RESULTS 
The patient population consisted of 67 VGB-treated pati-
ents, 41 males (61.2%) and 26 females (38.8%), with a mean
age of 13 yr (range; 6 6/12 yr to 21 yr old). Of the 67 patients,
15 (22%) had VFDs, which we attributed to VGB, and 52
(78%) did not. Of the patients with VGB-attributed VFDs,
13 had nasal arcuate type, 1 had nasal and temporal constrict-
ed type, and 1 had nasal constricted type (Table 1). Seven pa-
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Fig. 1. Four separate and increasingly severe cases of VBG-attributed field defects, as determined by automated static threshold perime-
try using Humphrey Field Analyzer Program 30-2. (A) Grade I (minimal, 25-30° ), (B) Grade II (moderate, 20-30° ), (C) Grade III (moderate
to severe, <20° ), (D) Grade IV (severe, ring scotoma).
Type Number of patients
Nasal arcuate 13
Nasal and temporal arcuate 1
Nasal constricted 1
Table 1. Type of vigabtrin-attributed visual field defects
Severity Number of patients
Grade I (minimal, 25-30° )7
Grade II (moderate, 20-30° )5
Grade III (moderate to severe, <20° )2
Grade IV (severe, ring scotoma) 1






Male 10 31 p>0.05
Female 5 20 (Fisher’s exact test)
Age of onset of treatment
Mean (yr) 9.9±2.5 8.8±3.4 p>0.05 (t-test)
Duration of treatment at follow-up
Mean (yr) 4.4±1.3 4.0±1.8 p>0.05 (t-test)
Total dose of vigabatrin
Mean (g/kg) 23.2±12.1 22.3±17.3 p>0.05(t-test)
Adjunct or monotherapy
Add-on therapy 10 31 p>0.05
monotherapy 5 20 (Fisher’s exact test)
Seizure type
CPS±2° GTCS 14 47
SPS 1 3
GTCS 1 1
Structural abnormality in the brain
Yes 7 9 p>0.05 (t-test)
No 14 37
Table 3. Patient baseline demographic and clinical data
VFD, visual field defects; CPS, complex partial seizure; GTCS, general-
ized tonic-clonic seizure; SPS, simple partial seizure.730 S.J. You, H.S. Ahn, T.-S. Ko
tients had Grade I VGB-attributed VFDs, 5 had Grade II,
2 had Grade III, and 1 had Grade IV (Table 2). To identify
potential risk factors for VGB-attributed VFDs, we compared
the VFD and non-VFD patient groups with respect to medi-
cations and other clinical parameters. There were no signifi-
cant differences between the VFD and non-VFD patients in
terms of mean age at the beginning of treatment, total treat-
ment duration, cumulative VGB dose, maximum VGB dose,
sex distribution, structural abnormalities in the brain, or whe-
ther VGB was given alone or in conjunction with another
drug (p>0.05 each) (Table 3). However, there were no cases
of VGB-attributed VFDs in patients with total treatment
durations <2 yr (Table 4) and cumulative doses <10 g/kg
(Table 5). 
DISCUSSION 
Our results indicate that the prevalence of VFDs in VGB-
treated children is 22%. This is consistent with recent reports
of VFD prevalences ranging from 15 to 20% in western chil-
dren (7, 13-17), but is lower than the about 30% previously
observed in VGB-treated children. This may be due to our
patient population, which was limited to older patients capa-
ble of cooperating with ophthalmologic and visual field exam-
inations. The exclusion of younger patients may have decre-
ased the estimated prevalence of VGB-associated VFDs, because
these younger patients, especially those with infantile spasms,
require high dose, sustained treatment with VGB and might
be more prone to VFDs. In addition, we used automated
static perimetry to detect VGB-attributed VFDs, which may
have influenced our results. The utilized 30-2 Humphrey
Field Analyzer has the advantages of being generally avail-
able, investigator independent, easy to use, simple to stan-
dardize, and highly effective at detecting nasal field defects.
However, because of its limited spatial context, the Humphrey
Field Analyzer may miss mild to moderate visual field defects
in the temporal fields. These are more reliably demonstrat-
ed by other techniques, such as kinetic (Goldmann) perime-
try (10, 18). However, VGB-associated VFDs typically pre-
sent as concentric peripheral losses that are most severe nasal-
ly, with relatively milder temporal losses; these characteris-
tics indicate that although some mild-to-moderate defects
may be underestimated using this technique, the static Hum-
phrey Field Analyzer should reliably detect VGB-attributed
VFDs.
A final limitation in the present work is our inability to
conclusively identify a causal link between VGB therapy and
the observed VFDs; for this to be possible, we would have
to enroll only patients who had completed VFD testing prior
VGB therapy, which is rare. However, this is a limitation in
most, if not all, retrospective studies on pediatric VBG-attri-
buted VFDs. Here, we believe that the noted VFDs are VGB-
attributed VFDs because they have the nasal-dominated pat-
tern that is characteristic of VGB-attributed VFDs but is not
seen in VFDs due to other causes.
Interestingly, our analysis did not reveal any correlations
between the incidence of VGB-associated VFDs and the mean
age at the beginning of treatment, total treatment duration,
cumulative dose or maximum dose. However, we did note
that no VGB-attributed VFDs were seen in patients with
total treatment durations <2 yr and cumulative doses <10
g/kg. The latter trends are consistent with previous findings
in adults, wherein longer treatment durations (5) and higher
total doses of VGB (7) were associated with greater losses in
visual fields. These possible associations are particularly im-
portant in pediatric patients, because high dose, sustained
VGB treatment is commonly used to treat infantile spasms,
especially those from tuberous sclerosis (19). If the treatment
duration and cumulative dose of VGB are related to VFD,
shorter treatments or lower doses should be investigated by
linear regression analysis and prospective trials for their abili-
ties to be therapeutically effective while minimizing the occur-
rence of VFDs. Another important finding was that the most
common type of VGB-attributed VFD in our study popu-
lation was the nasal arcuate type, and that severity Grades I
and II were most frequent. These findings are consistent with
previous reports that VGB-associated VFDs involve the nasal
field (10), and indicate that automated perimetry is likely
to be more reliable for identifying VGB-associated VFDs.
However, automated perimetry tends not to lend itself to
assessment of pediatric patients, suggesting the need for more
reliable and cooperation-independent testing methods. 
While VGB-attributed VFD was originally considered
irreversible (20), more recent studies have shown that this






<2 yr 0 11 11
2≤ and <4 yr 6 13 19
4≤ and <6 yr 7 22 29
≤6 yr 2 6 8
Total 15 52 67
Table 4. Comparisons of treatment duration
VFD, visual field defects.
With VFD
(Group A)
Total cumulative dose VGB




<10 0 10 10
10≤ and <20 8 23 31
20≤ and <30 2 7 9
30≤ and <40 3 4 7
40≤ and <50 2 4 6
50≤ 04 4
Total 15 52 67
Table 5. Comparisons of total cumulative dose
VGB, vigabatrins; VFD, visual field defects.Vigabatrin and Visual Field Defects 731
24, 25) patients after discontinuation of VGB therapy. These
reports suggested that patients can recover their retinal func-
tion despite apparently permanent damage to retinal cells.
Although the mechanism by which VGB causes VFD is still
not known, studies have suggested that VGB causes a gen-
eral defect in the retinal network rather than damaging the
outer retinal layer (26). Theoretically, such a defect could func-
tionally recover, at least to some extent, in younger people
whose neuronal systems still possess significant plasticity. In
the future, it may be possible to perform follow-up visual
field examinations on our study population, in an effort to
examine reversibility in pediatric patients.
In sum, the results of the present study suggest that VFD
occurs in VGB-treated children, but at a lower prevalence
than that seen in adults (5, 9-11, 14, 26-29). Our results also
suggest that there is a relationship between VGB-attributed
VFDs and the duration and total dose of VGB. Therefore,
we recommend that the total dose and duration of VGB treat-
ment should be reduced as much as possible, and that patients
receiving VGB should be given visual field examinations
prior to VGB treatment, and at regular intervals thereafter.
Overall, the clinical decision to use VGB should be based
on a risk-benefit analysis of each individual case.
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